These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21194162)

  • 1. A case series of peripheral neuropathy in patients with Parkinson's disease.
    Gondim Fde A; de Oliveira GR; Peixoto AA; Horta WG
    Ann Neurol; 2010 Dec; 68(6):973-5; author reply 975. PubMed ID: 21194162
    [No Abstract]   [Full Text] [Related]  

  • 2. Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy.
    Urban PP; Wellach I; Faiss S; Layer P; Rosenkranz T; Knop K; Weis J
    Mov Disord; 2010 Aug; 25(11):1748-52. PubMed ID: 20740570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropathy as a potential complication of levodopa use in Parkinson's disease.
    Toth C; Brown MS; Furtado S; Suchowersky O; Zochodne D
    Mov Disord; 2008 Oct; 23(13):1850-9. PubMed ID: 18785232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reply: neuropathy as a potential complication of levodopa use in Parkinson's disease: a pharmacological and pharmacovigilance point of view.
    Toth C; Suchowersky O; Zochodne D
    Mov Disord; 2010 Mar; 25(4):525. PubMed ID: 20155864
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens.
    Mancini F; Comi C; Oggioni GD; Pacchetti C; Calandrella D; Coletti Moja M; Riboldazzi G; Tunesi S; Dal Fante M; Manfredi L; Lacerenza M; Cantello R; Antonini A
    Parkinsonism Relat Disord; 2014 Jan; 20(1):27-31. PubMed ID: 24099722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Has "levodopa-induced neuropathy" been reported in Parkinson's disease clinical trials?
    Teodoro T; Pires D; Rosa MM; Coelho M; Sampaio C; Ferreira JJ
    Mov Disord; 2011 Aug; 26(10):1966-7. PubMed ID: 21567458
    [No Abstract]   [Full Text] [Related]  

  • 7. Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study.
    Ceravolo R; Cossu G; Bandettini di Poggio M; Santoro L; Barone P; Zibetti M; Frosini D; Nicoletti V; Manganelli F; Iodice R; Picillo M; Merola A; Lopiano L; Paribello A; Manca D; Melis M; Marchese R; Borelli P; Mereu A; Contu P; Abbruzzese G; Bonuccelli U
    Mov Disord; 2013 Sep; 28(10):1391-7. PubMed ID: 23836370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Double crush" in Parkinson's disease.
    Weinberger M; Inzelberg R
    Ann Neurol; 2010 Dec; 68(6):972; author reply 973. PubMed ID: 21194160
    [No Abstract]   [Full Text] [Related]  

  • 9. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease.
    Toth C; Breithaupt K; Ge S; Duan Y; Terris JM; Thiessen A; Wiebe S; Zochodne DW; Suchowersky O
    Ann Neurol; 2010 Jul; 68(1):28-36. PubMed ID: 20582991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current controversies: levodopa in the treatment of Parkinson's disease.
    Sharma JC; Vassallo M; Ross IN
    Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
    [No Abstract]   [Full Text] [Related]  

  • 11. Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy.
    Manca D; Cossu G; Murgia D; Molari A; Ferrigno P; Marcia E; Melis M
    Mov Disord; 2009 Nov; 24(15):2293-4. PubMed ID: 19795477
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment with levodopa and risk for malignant melanoma.
    Olsen JH; Tangerud K; Wermuth L; Frederiksen K; Friis S
    Mov Disord; 2007 Jul; 22(9):1252-7. PubMed ID: 17534943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
    Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa elevates homocysteine: is this a problem?
    O'Suilleabhain P; Diaz-Arrastia R
    Arch Neurol; 2004 May; 61(5):633-4. PubMed ID: 15148136
    [No Abstract]   [Full Text] [Related]  

  • 15. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease.
    Zoldan J; Friedberg G; Weizman A; Melamed E
    Adv Neurol; 1996; 69():541-4. PubMed ID: 8615178
    [No Abstract]   [Full Text] [Related]  

  • 16. Yawning in Parkinson's disease.
    Evidente VG; Hardy KG
    Neurology; 1999 Jan; 52(2):428. PubMed ID: 9932981
    [No Abstract]   [Full Text] [Related]  

  • 17. Yawning in Parkinson's disease.
    O'Sullivan JD; Lees AJ; Hughes AJ
    Neurology; 1999 Jan; 52(2):428. PubMed ID: 9932982
    [No Abstract]   [Full Text] [Related]  

  • 18. Yawning in Parkinson's disease.
    Colosimo C; Pontieri FE
    Neurology; 1999 Jan; 52(2):428. PubMed ID: 9932980
    [No Abstract]   [Full Text] [Related]  

  • 19. Hiccups associated with levodopa in Parkinson's disease.
    Gerschlager W; Bloem BR
    Mov Disord; 2009 Mar; 24(4):621-22. PubMed ID: 19185020
    [No Abstract]   [Full Text] [Related]  

  • 20. [Secondary effects of chronic treatment with levodopa in Parkinson disease].
    Baltag D; Ignat B; Manole OZ
    Rev Med Chir Soc Med Nat Iasi; 2003; 107(1):131-5. PubMed ID: 14755983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.